Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon NvfiledCriticalOrganon Nv
Publication of MY143679ApublicationCriticalpatent/MY143679A/en
Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
Y02P20/00—Technologies relating to chemical industry
Y02P20/50—Improvements relating to the production of bulk chemicals
Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
Steroid Compounds
(AREA)
Abstract
1 8 150-SUBSTITUTED STEROIDS HAVING SELECTIVE ESTROGENIC ACTIVITY 5 ABSTRACT THE INVENTION PROVIDES 15P-SUBSTITUTED STEROIDAL COMPOUNDS HAVING SELECTIVE ESTROGEN RECEPTOR ACTIVITY ACCORDING TO FORMULA L OR 4 H R3 10 R 0 R WHEREIN. R1 IS H, CI-5ALKYL. CI-12ACYL, DI-(C1-5ALKYL)AMINOCARBONYL, (CI-5ALKYL)OXYCARBONYL OR 15 SULFAMOYL, R 2IS H. CI 3 ALKYL, C23ALKENYL ORC2-3 ALKYNYL, EACH OF WHICH MAY BE OPTIONALLY SUBSTITUTED WITH A HALOGEN, R3 IS CI-2 ALKYL, ETHENYL OR ETHYNYL, EACH OF WHICH MAY BE OPTIONALLYSLIBSTITUTED WITH A HALOGEN, AND 20 R' IS H OR C1,12 ACYL D CFO Q 1@.-
MYPI20054157A2004-09-082005-09-0515b-subsitituded streoids having selective estrogenic activity
MY143679A
(en)
Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol